Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)

This publication has 45 references indexed in Scilit:

• Combination Chemotherapy with Paclitaxel, Estramustine and Carboplatin for Hormone Refractory Prostate Cancer
  Journal of Urology, 2002
• Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration
  Journal of Clinical Oncology, 2002
• Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480
  Journal of Clinical Oncology, 2002
• A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER—EVIDENCE FOR DEFERRED TREATMENT
  Journal of Urology, 2001
• Living With Treatment Decisions: Regrets and Quality of Life Among Men Treated for Metastatic Prostate Cancer
  Journal of Clinical Oncology, 2001
• A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma
  Cancer, 2000
• Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
  Journal of Clinical Oncology, 1999
• Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer
  JNCI Journal of the National Cancer Institute, 1999
• How Much Can We Rely on the Level of Prostate-Specific Antigen as an End Point for Evaluation of Clinical Trials? A Word of Caution!
  JNCI Journal of the National Cancer Institute, 1996
• Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy
  Cancer, 1992